Merck, Targovax Team Up for New Mesothelioma Clinical Trial

Standard-of-care treatment for malignant mesothelioma could change significantly, depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The mesothelioma clinical trial will involve pembrolizumab, also known by the brand name Keytruda, and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma patients when used with chemotherapy. Together, there is potential for a much greater impact in significantly extending patient survival. The clinical trial is a partnership between Targovax, a small Scandinavian biotech company that produces ONCOS-102, and the pharmaceutical company Merck &Co. Inc., which manufactures Keytruda. “We could end up with a very powerful immunotherapy combination,” Dr. Magnus Jaderberg, chief medical officer at Targovax, told The Mesothelioma Center at “Standard of care will likely change in the next couple years. There is a good chance ONCOS-102 could be part of that.” Synergy of Mesothelioma Treatments Critical First-line standard of care for pleural mesothelioma patients today — intravenous use of pemetrexed (Alimta) and cisplatin chemotherapy — has not changed for almost two decades, limiting patients to a median 12-month overall survival rate. In 2019, the U.S. Food and Drug Administration did approve the use of Tumor Treating Fields, which utilize...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
CONCLUSIONS: Immunohistochemistry seems to be a promising option not only in clinical recognition, but also in the selection and monitoring of treatment effects. However, these methods have not yet recommended for routine clinical use. PMID: 33032462 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Ohtsuka
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I Abstract The tumour-associated antigen 5T4 is an attractive target for cancer immunotherapy. However to date, reported 5T4-specific cellular immune responses induced by various immunisation platforms have been largely weak or non-existent. In the present study, we have evaluated a heterologous prime boost regime based on the simian adenovirus ChAdOx1 and modified vaccinia virus Ankara (MVA) expressing 5T4 for immunogenicity and tumour protective efficacy in a mouse cancer model. Vaccination-induced immune responses were strong, durable and attrib...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases. The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses. Researchers are administering the immunotherapy drug as first-line therapy in combination with chemotherapy using pemetrexed and cisplatin. “Based on what we’ve seen in our first study of patients with various solid tumor types, which is good tolerance and response in a couple ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: immunotherapy clinical trial immunotherapy for cancer mesothelioma mesothelioma clinical trials mesothelioma immunotherapy ONCOS 102 Source Type: news
More News: Adenoviruses | Alimta | Asbestosis | Biotechnology | Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Genetics | Immunotherapy | Melanoma | Merck | Mesothelioma | Ovarian Cancer | Ovaries | Partnerships | PET Scan | Prostate Cancer | Skin Cancer | Study | Yervoy